Department of Pharmacy, Hôpital Cochin, Assistance Publique - Hôpitaux de Paris, France.
Department of Rheumatology, Paris Descartes University, Hôpital Cochin, Assistance Publique - Hôpitaux de Paris; INSERM (U1153), Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, Paris, France.
Clin Exp Rheumatol. 2021 Jul-Aug;39(4):811-818. doi: 10.55563/clinexprheumatol/pzc5lo. Epub 2020 Oct 9.
In spondyloarthritis (SpA), improving patients' knowledge on their biologics is a key factor to enhance adherence. The information given to the patient has to ensure the acquisition of safety skills regarding their treatment. The aims of this trial were to evaluate the impact of a pharmacist's educational interview on knowledge and adherence to biologics in these patients.
Consecutive adult patients with well-controlled axial SpA, stable on biologics were enrolled in a randomised, controlled, single-centre, open-label, 6-month trial. A pharmacist's educational interview provided information on biologics management at baseline in the intervention group and at month 6 in the control group. The changes in a weighted knowledge score concerning the management of biologics and the change in the Medication Possession Ratio (MPR) at month-6 were primary outcomes. The changes in disease activity (BASDAI) and patients' satisfaction regarding the pharmacists' interview were secondary outcomes.
Patients' characteristics at baseline were comparable among the 89 included patients (46 in the intervention group, 43 in the control group). The patient's knowledge score concerning biologics management improved at a greater magnitude in the educational group (+11.0±11.5 vs. +3.0 ±10.6 in the intervention versus the control group, respectively, p<0.0001). There was also a trend in a better adherence (+2.2±13.9 vs. -0.6±18.9 in the intervention versus the control group, respectively, p=0.691). The disease activity remained stable in both groups.
This study is strongly in favour of the benefit of a pharmacist's educational interview in the management of patients with axial SpA.
在脊柱关节炎（SpA）中，提高患者对生物制剂的认识是增强依从性的关键因素。给予患者的信息必须确保其获得与治疗相关的安全技能。本试验的目的是评估药剂师教育性访谈对这些患者的生物制剂知识和依从性的影响。
连续纳入了生物制剂治疗控制良好的、稳定的中轴型 SpA 成年患者，进行了一项随机、对照、单中心、开放标签、6 个月的试验。在干预组中，在基线时和对照组中在第 6 个月时，药剂师进行了教育性访谈，提供生物制剂管理信息。管理生物制剂的加权知识评分的变化和第 6 个月时的药物使用剂量比（MPR）的变化是主要结局。疾病活动（BASDAI）的变化和患者对药剂师访谈的满意度是次要结局。
89 例纳入患者的基线特征在两组之间具有可比性（干预组 46 例，对照组 43 例）。教育组患者对生物制剂管理的知识评分提高幅度更大（+11.0±11.5 与干预组和对照组分别为+3.0±10.6，p<0.0001）。依从性也有改善的趋势（+2.2±13.9 与干预组和对照组分别为-0.6±18.9，p=0.691）。两组的疾病活动均保持稳定。
这项研究强烈支持药剂师教育性访谈在管理中轴型 SpA 患者方面的益处。
